Brand Name
Relafen
Generic Name
Nabumetone
View Brand Information FDA approval date: February 25, 2002
Classification: Nonsteroidal Anti-inflammatory Drug
Form: Tablet
What is Relafen (Nabumetone)?
Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment